Axicabtagene Ciloleucel
Recurrent Diffuse Large B-Cell Lymphoma
Zhujiang HospitalCell therapyPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 62/ 100
- Competitive Position
- 73/ 100
Competitive context
107 Active assets in the Recurrent Diffuse Large B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Selinexor Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 3 | BB |
DEXAMETHASONE City of Hope Medical Center | Phase 2/3 | BB |
ETOPOSIDE University of California, Davis | Phase 3 | BB |
Ifosfamide University of California, Davis | Phase 3 | BB |
Cyclophosphamide Nathan Denlinger | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Axicabtagene Ciloleucel is also rated in:
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaDormant
BBB
Indicative ·
77 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →